This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Encompass Health (EHC) Up 4.7% Despite Q2 Earnings Miss
by Zacks Equity Research
Encompass Health (EHC) intends to open three additional de novo locations and increase the bed count by 20 in existing facilities this year.
Community Health (CYH) Down 30.3% Since Q2 Earnings Report
by Zacks Equity Research
Community Health (CYH) expects capex to remain within $400-$450 million in 2022.
Agenus (AGEN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Agenus (AGEN) delivered earnings and revenue surprises of 26.09% and 11.93%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Teladoc (TDOC) Down 10.3% Despite Q2 Earnings & Sales Beat
by Zacks Equity Research
Teladoc (TDOC) projects total visits between 4.8 million and 5 million for the third quarter.
Heska (HSKA) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Heska (HSKA) delivered earnings and revenue surprises of -8.11% and 6.62%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Centene (CNC) Q2 Earnings Beat Estimates, Boosts 2022 View
by Zacks Equity Research
Centene (CNC) currently has $3.4 billion remaining in its share buyback program.
Agenus (AGEN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Agenus (AGEN) delivered earnings and revenue surprises of 34.48% and 49.50%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Agenus (AGEN) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Agenus (AGEN) delivered earnings and revenue surprises of -62.50% and 46.30%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Do Options Traders Know Something About Agenus (AGEN) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Agenus (AGEN) stock based on the movements in the options market lately.
Company News for Nov 10, 2021
by Zacks Equity Research
Companies in the news are: DHI, AGEN, IGT, NSANY
Editas (EDIT) Q3 Earnings Beat Estimates, Revenues Fall Y/Y
by Zacks Equity Research
Editas (EDIT) reports narrower-than-expected loss in the third quarter of 2021 while its revenues marginally beat estimates. Focus remains on the development of lead candidate, EDIT-101.
Apellis' (APLS) Q3 Loss Widens, Revenues Surpass Estimates
by Zacks Equity Research
Apellis (APLS) reports wider-than-expected loss for the third quarter of 2021 while revenues surpass expectations.
Agenus (AGEN) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Agenus (AGEN) delivered earnings and revenue surprises of 50.00% and 38.15%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Allogene (ALLO) Misses on Q3 Earnings, Addresses Clinical Hold
by Zacks Equity Research
Allogene (ALLO) misses earnings estimates for the third quarter. However, the stock rises in after-market trading.
Global Blood's (GBT) Earnings & Revenues Lag Estimates in Q3
by Zacks Equity Research
Global Blood (GBT) reports wider-than-expected loss in the third quarter of 2021 while its revenues miss estimates.
Horizon's (HZNP) Q3 Earnings Beat Estimates, 2021 Guidance Up
by Zacks Equity Research
Horizon's (HZNP) earnings and revenues beat estimates in the third quarter of 2021. The company lifts net sales guidance for 2021.
Ultragenyx's (RARE) Q3 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Ultragenyx (RARE) reports narrower-than-expected loss in the third quarter of 2021 while revenues surpass estimates.
Agenus (AGEN) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Agenus (AGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Down 33.3% in 4 Weeks, Here's Why Agenus (AGEN) Looks Ripe for a Turnaround
by Zacks Equity Research
The heavy selling pressure might have exhausted for Agenus (AGEN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Agenus (AGEN) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Agenus (AGEN) delivered earnings and revenue surprises of -54.17% and -36.75%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Agenus (AGEN) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Agenus (AGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bristol-Myers' (BMY) Q2 Earnings Beat, Opdivo Sales Grow
by Zacks Equity Research
Bristol-Myers (BMY) beats on earnings and sales in the second quarter as Opdivo sales revive.
What Makes Agenus (AGEN) a Good Fit for "Trend Investing"
by Zacks Equity Research
Agenus (AGEN) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Vertex (VRTX) Initiates Phase II Study on Pain Candidate
by Zacks Equity Research
Vertex (VRTX) starts phase II study for VX-548 to treat acute pain after bunionectomy surgery & expects to start another phase II study to treat acute pain after abdominoplasty surgery in a few weeks.
Moving Average Crossover Alert: Agenus (AGEN)
by Zacks Equity Research
Agenus (AGEN) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.